The Substance Abuse and Mental Health Services Administration yesterday issued guidance for health care and addiction professionals using methadone, naltrexone or buprenorphine to treat patients with opioid use disorder. Mandated by the Comprehensive Addiction and Recovery Act, the guidance offers appropriate prescribing practices and strategies for supporting patients. It also educates patients, families and the general public about the medications. “We know that people can and do recover from opioid use disorders when they receive appropriate treatment, and medication-assisted treatment’s success in treating opioid use disorders is well documented,” said Elinore McCance-Katz, M.D., assistant secretary for mental health and substance use at the Department of Health and Human Services. For an AHA toolkit and other resources to help hospitals and health systems tackle the opioid crisis, visit www.aha.org/opioidtoolkit.

Related News Articles

Headline
The Food and Drug Administration Friday approved the first generic naloxone nasal spray, an emergency treatment for opioid overdose intended for use in the…
Headline
April 27 is National Prescription Drug Take Back Day, an opportunity for the public to safely dispose of unwanted or expired prescription pills at sites…
Headline
The National Institutes of Health today selected several universities to partner with communities in Kentucky, Massachusetts, New York and Ohio to study the…
Headline
The Food and Drug Administration yesterday announced changes to the prescribing information included in outpatient opioid pain medication labels.
Headline
The Agency for Healthcare Research and Quality is accepting comments through April 25 on a draft report on treatment for acute pain.
Headline
The Department of Health and Human Services this week awarded $487 million in fiscal year 2019 grants to help states and territories increase access to…